Quest Magazine

ABC Television Network Is New Home of MDA Show of Strength Telethon

BioBlast Pharma Receives FDA Fast Track Designation for Treatment of Oculopharyngeal Muscular Dystrophy

Santhera Receives FDA Fast Track Designation for Treatment of Duchenne Muscular Dystrophy

Kroger-Atlanta Division Raises More Than $292,000 Through MDA Shamrock Program To Help People Fighting Muscle Disease

MDA Ride for Life XXVIII Partners with Camelback Resort in the Fight Against Muscle Disease

ALS Research Update: Spring 2015

Understanding the many roads that can lead to amyotrophic lateral sclerosis (ALS) is a painstaking but necessary prerequisite to development of disease-modifying treatments. Recently, several research teams have made contributions to this effort. A 2011 MDA career development grant to Adrian Israelson, who was then at the University of California, San Diego, was crucial to the finding that the MIF protein counteracts the effects of ALS-causing mutations in the SOD1 gene.

Tempaper and MDA Team Up in the Fight Against Muscle Disease

New Guideline for CMD Diagnosis and Care

This spring, the American Academy of Neurology (AAN) released a guideline for the diagnosis and care of children with congenital muscular dystrophy (CMD), a group of early-onset, genetic disorders that can involve skeletal (including respiratory) muscle weakness, heart problems, brain and eye abnormalities, and contractures (frozen joints).

An early-onset disease with many genetic causes

CMD: Phase 1 Omigapil Trial Remains Open

Santhera Pharmaceuticals continues to recruit participants for a phase 1 trial of omigapil in children and adolescents with the type 1A form of congenital muscular dystrophy (CMD)

MDA to Offer Genetic Testing for Limb-Girdle Muscular Dystrophy

Pages